None listed
Conditions
Interventions
Others(Topical moisturizer application) : Intervention Name: Topical Application of Dexeryl® MD Cream
Intervention Description: Dexeryl® MD cream containing 15% glycerin and 10% paraffin will be topi
Sponsors
Hanyang University Seoul Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: a. Individuals who experience pruritus. b. Individuals with objectively confirmed impaired skin barrier function, verified through instrumental measurement. Example: Subjects whose transepidermal water loss (TEWL) value at the test site is =12 g/m²/h when measured using a Tewameter® TM300 (Courage + Khazaka electronic GmbH, Germany). c. Individuals who understand the purpose and procedures of the study and voluntarily express willingness to participate. d. Individuals who are able to comply with follow-up assessments throughout the study period. e. Individuals who understand the purpose of the study and provide written informed consent to participate.
Exclusion criteria
Exclusion criteria: a. Individuals whom a dermatologist (board-certified specialist or resident) determines to have an active skin disease requiring medical treatment. b. Individuals with an ESIF (erythema, scaling, induration, fissuring) score greater than 6 at the time of screening. c. Individuals who have received antibiotics, corticosteroids, immunosuppressants, antihistamines, retinoids, or phototherapy for dermatologic conditions within 4 weeks prior to screening. (However, topical treatments that do not affect the test site may be permitted at the discretion of the principal investigator.) d. Individuals with artificially induced damage to the skin barrier at the test site by physical or chemical methods (e.g., exfoliation procedures, peeling agents) within 4 weeks prior to screening. e. Individuals who have taken herbal medicine or health supplements, or who have applied moisturizers to the test site for the improvement of skin conditions within 2 weeks prior to screening. f. Individuals currently participating in another clinical trial or human application test. g. Individuals who have participated in a similar human application test within 4 weeks prior to screening. h. Individuals who are sensitive or allergic to cosmetics. i. Pregnant or breastfeeding women, or individuals who may become pregnant during the study period and who are not using medically acceptable methods of contraception.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS Pruritus Score;transepidermal water loss ;skin hydration | — |
Secondary
| Measure | Time frame |
|---|---|
| erythema, scaling, induration, fissuring (ESIF) scale;Subject Satisfaction Score | — |
Countries
Korea, Republic of
Contacts
Public ContactMin Young Kim
Hanyang University
Outcome results
None listed